In this exclusive webinar, we are joined by Dr Cecilia Marcacci, Director of prestigious Monte Carlo Clinic in Monaco and member of the sientific committee of the French Society of Hair Transplantation. Dr Marcacci shares her multimodality approach, which combines advanced protocols to improve patient outcomes.
The Future of Hair Renewal: Mastering Multimodality Protocols
This video highlights key insights discussed, including:
The Diagnostic Key: Why Dr Marcacci utilises trichoscopy and other diagnostic approaches to identify the specific type of hair loss—from Androgenetic Alopecia to Telogen Effluvium—before beginning treatment.
The Science of EXO-GROW™: Understanding the "new frontier" of synthetic bio-mimetic exosomes and their cell repair ability.
Pre- and Post-Transplant Optimisation: How exosomes can be used just weeks after a hair transplant to reduce "shock loss" and accelerate the growth of newly grafted follicles.
The Home Care Synergy: Why a 360-degree approach—including exosome-infused tonics and specialised supplements—is essential for long-term density.
Explore More Expert Strategies
Revolutionising Hair Restoration: Harnessing the Power of Exosomes with Dermapen 4™
Discover how it all works together to achieve your patients' skin goals.
Induce, Repair, Rejuvenate: A Dermatologist’s Comprehensive Approach to Skin Regeneration
Dr Irene Bermejo & Omar Kuri
Beyond the Graft: Revolutionary Hair Regeneration with EXO-GROW™
Want to take a deep dive into the topic? Read the information below for more
In the competitive world of aesthetic medicine, hair restoration is one of the fastest-growing niches. However, as Dr Cecilia Marcacci explains from her clinic in Monaco, success requires more than a procedure; it requires a deep understanding of the biological triggers of hair loss and the latest regenerative technologies.
Dr Marcacci emphasises that a successful outcome begins with a microscopic look at the scalp and combined with DNA and blood tests. Using Trichoscopy, she evaluates the diameter of the hair, the condition of the follicular units, and the presence of inflammation or fibrosis.
Androgenetic Alopecia: Identifying the miniaturisation caused by DHT.
Telogen Effluvium: Recognising the diffuse loss often triggered by stress, nutrition, or illness.
Traction Alopecia: Spotting the early signs of fibrosis caused by repetitive pulling (common in dancers and certain cultural hairstyles) before the loss becomes permanent.
The webinar introduces EXO-GROW™, a "bio-mimetic" synthetic exosome. Unlike traditional exosomes derived directly from human or animal tissue, these are lab-created to mimic the human body's natural messengers.
Safety First: Because they are synthetic and purified, they pose no risk of genetic material transmission or immune rejection.
HLG Complex: This exclusive technology makes the exosomes "immune-tolerant," mimicking the way a placenta protects a fetus from the mother's immune system, ensuring the scalp accepts the treatment without inflammation.
The Payload: Each exosome carries a powerful mix of peptides, growth factors, Hyaluronic Acid, and ceramides directly to the hair bulb.
Dr Marcacci utilises the Dermapen 4™ to create controlled micro-perforations in the scalp (usually at depths of 0.5mm to 1.0mm). This serves two purposes:
Direct Stimulation: The micro-injury itself triggers the release of the body's own growth factors.
Enhanced Delivery: It creates "channels" that allow the EXO-GROW™ molecules to bypass the skin barrier and reach the target follicular cells.
Dr Marcacci notes that even for "laser-phobic" patients or those sensitive to pain, this protocol is highly tolerable and provides a pink, re-vascularized scalp colour—a sign of increased blood flow.
The primary goal of the Marcacci Protocol is to prolong the Anagen (growth) phase of the hair cycle. By stimulating "sleeping" follicles, her clinical results show a significant increase in density (moving, for example, from 140 to 208 hairs per square centimetre) and visible thickening of the hair shaft within six months of treatment.
For hair transplant patients, the recovery period is critical. Dr Marcacci highlights that while injections are often prohibited immediately following a transplant, Dermapen 4™ and Exosomes can be safely introduced as early as four weeks post-op. This reduces the common "shock loss" (temporary shedding of old hair) and ensures the new grafts have the nutrient-rich environment they need to thrive.
As Dr Marcacci concludes, the future of hair restoration lies in "Personalised Regenerative Medicine." By combining the mechanical precision of Dermapen 4™ with the complex chemical signalling of EXO-GROW™, practitioners can offer a safe, scientific, and highly effective solution for hair loss that goes far beyond traditional topical treatments.
